Organovo to Present at Raymond James Life Sciences and MedTech Conference
13 June 2019 - 10:05PM
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology
company pioneering the development of 3D bioprinted tissues aimed
at treating a range of serious adult and pediatric liver diseases,
today announced that Chief Executive Officer Taylor J. Crouch is
scheduled to speak at the Raymond James Life Sciences and MedTech
Conference in New York on Tuesday, June 18, 2019 at 1:15pm Eastern
Time (ET). The presentation will be simultaneously audio
webcast at http://www.organovo.com. The audio webcast will be
archived for seven days following the conference.
About Organovo Holdings, Inc.Organovo is a
biotech platform company that has developed a leadership position
with its revolutionary ability to 3D bioprint tissues with human
functionality. The Company is pursuing IND-track programs to
develop its NovoTissues® to address a number of serious unmet
medical needs, initially focusing on liver disease.
Organovo’s program for Alpha-1-antitrypsin deficiency received
orphan drug designation from the FDA in 2017. The Company is
also providing access to its ExVive™ in vitro tissue platform to
facilitate high value drug discovery and development
collaborations. Organovo’s wholly-owned subsidiary, Samsara
Sciences, provides the Company and its clients with high quality
human liver cells for research applications. Organovo is
changing the shape of life science research and transforming
medical care. Learn more at www.organovo.com.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts constitute forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. The factors that could cause the Company's
actual future results to differ materially from current
expectations include, but are not limited to, statements regarding
the potential benefits and therapeutic uses of the Company’s
therapeutic liver tissue, including the benefits of an orphan
designation; the Company’s expectations regarding the FDA
regulatory pathway and anticipated timelines for its regulatory
filings; the Company’s ability to successfully complete additional
preclinical studies, improve its manufacturing processes and
demonstrate the prolonged functionality and therapeutic benefits of
its therapeutic liver tissue; the Company’s ability to implement
clinical scale manufacturing and quality processes; the Company’s
ability to meet market demand; the Company’s ability to fund its
future operations and business plans; and acceptance of its disease
modeling and other in vitro tissue platforms. The factors
that could cause the Company's actual future results to differ
materially from current expectations include, but are not limited
to, risks and uncertainties relating to the Company’s ability to
successfully improve or demonstrate the durability and
functionality of its in vivo liver tissue candidate; the
possibility that the results of future preclinical studies may be
different from the Company’s earlier pilot studies and may not
support further clinical development of its tissue candidates; the
Company’s ability to successfully complete the required preclinical
and clinical trials required to obtain regulatory approval on a
timely basis or at all; the novelty of the Company’s therapeutic
tissue approach and the resulting heightened regulatory scrutiny,
delays in clinical development or delays in commercial acceptance;
the complexity of the manufacturing process for the Company’s
therapeutic tissues and the effort involved in developing GTP and
GMP facilities; the Company’s ability to raise significant
additional funds to support its business plan and its regulatory
objectives; the Company’s reliance on third parties and a single
supplier for clinical grade organs, including that the Company may
not be able to obtain sufficient raw materials to meet clinical or
commercial demand for its therapeutic products; competitive
products may adversely impact the market opportunity for the
Company’s therapeutic tissue candidates and its disease modeling
and other in vitro tissue products, services and technology; the
Company’s ability to successfully complete studies and provide the
technical information required to support market acceptance of its
disease modeling and other in vitro tissue products, services and
technology, on a timely basis or at all; and the Company’s ability
to comply with Nasdaq’s continued listing requirements. These
and other factors are identified and described in more detail in
the Company's filings with the SEC, including its Annual Report on
Form 10-K filed with the SEC on June 3, 2019. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date that they were made. These
cautionary statements should be considered with any written or oral
forward-looking statements that the Company may issue in the
future. Except as required by applicable law, including the
securities laws of the United States, the Company does
not intend to update any of the forward-looking statements to
conform these statements to reflect actual results, later events or
circumstances or to reflect the occurrence of unanticipated
events.
Investor & Press Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Oct 2023 to Oct 2024